KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2025)

Ginkgo Bioworks Holdings' Capital Expenditures history spans 6 years, with the latest figure at $5000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 99.96% year-over-year to $5000.0; the TTM value through Dec 2025 reached $7.7 million, down 87.74%, while the annual FY2025 figure was $7.7 million, 87.74% down from the prior year.
  • Capital Expenditures reached $5000.0 in Q4 2025 per DNA's latest filing, down from $38000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $27.0 million in Q2 2024 to a low of $5000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $11.6 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 443.04% in 2023, then tumbled 99.96% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $5.1 million in 2021, then soared by 401.47% to $25.6 million in 2022, then crashed by 86.56% to $3.4 million in 2023, then surged by 297.85% to $13.7 million in 2024, then crashed by 99.96% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNA's Capital Expenditures are $5000.0 (Q4 2025), $38000.0 (Q2 2025), and $7.6 million (Q1 2025).